Biohub, formerly Bridgebio, is committed to creating the most innovative medtech and biotech companies that will reshape healthcare industry. It has been selected as the most favorable biomedical park for returnees by China Entrepreneur Magazine, and has been ranked as the top 50 incubators in China. Biohub strives to become the most international and professional incubator and investment platform for healthcare innovation in China.

Since its establishment in 2011, Biohub has launched its well tailored incubation programs to incubate and accelerate healthcare innovations. Relying on its advanced combination of vertical incubation and professional investment , Biohub operates the top-tier biomedical parks, and provides customized acceleration services for domestic and foreign medical startups. Biohub has formed an international ecosystem which consists international bioparks, well-known pharmaceutical and medtech companies, venture capital institutions, hospitals and clinicans KOLs etc.

With its unique vertical incubation model , Biohub has introduced，incubated and invested 100+ innovative medical projects.

Targeting the major unmet medical needs in China and searching for the disruptive medtech innovation around the world, Biohub selects the First-class team and top industry experts, and then incubates and invests in these healthcare unicorns in domains of cardiovascular diseases, ophthalmology, cancer diagnosis, IVD, immune cell therapy and multi-target biological drugs, to fill the gap between research and commerticalization. Till now, Biohub has incubators and accelerators in top tier life science clusters ofWuhan, Suzhou, Chongqing, Chengdu, Zhengzhou, and Boston, providing offices, lab space, GMP facilities. The revolutionary medtech acceleration model proposed by Biohub can effectively shorten their industrialization process by 1-2 years.

Biohub  offers  direct investment for innovative projects from early stage to growth stage  

Our strategic partner Proxima Ventures is set up in Shanghai and manages 3 RMB funds and 1 USD fund.  Targeting from early  to growth stage.projects and focusing the major unmet clinical needs, Proxima invests in the fast-growing companies with disruptive innovations in the healthcare industry, in particular in the domains of cardiovascular diseases, ophthalmology, digestive systems, respiratory systems, oncology, interventional therapy, and innovative materials. Commited to building the innovation ecosystem and supporting outstanding entrepreneurs . Proxima has invested in more than 50 domestic and foreign innovative medical device companies.